ESMO Update: State of the Art in Early Phase Oncology Trial Design

Clinical Trials, Life Sciences, Pharmaceutical,
  • Wednesday, November 14, 2018 | 8:30am EST (NA) / 1:30pm GMT (UK) / 2:30pm CET (EU-Central)
  • 60 min

Video coming soon

The science looks promising and you have secured vital funding to take your compound to the clinical stage. What is the best strategy for operationalizing your oncology study in a clinical setting to meet your business objectives?

Aimed at small and mid-size companies with oncology assets, this 1-hour webinar will present the theory behind Phase I oncology studies, as well as the practical and logistical challenges, when taking your compound into the clinic.

Join Dr. Alain Thibault and Dr. Ahmad Awada as they provide insights from key ESMO 2018 presentations likely to influence the future of early phase oncology drug development.

The webinar will be split into four parts, including:

  1. An introduction into how Phase I studies have evolved to meet development objectives 
  2. A discussion of where Phase I design is heading, with a look at whether 3+3 is still the gold standard and what could replace it
  3. The importance of pre-feasibility consultation with specialist oncology sites 
  4. A live Q&A with expert speakers

Speakers

Alain Thibault, MD, US National Cancer Institute Training, Senior Medical Director, Early Phase Oncology Trials, Simbec-Orion Group

Dr. Alain Thibault has gained a wealth of clinical development experience in oncology, both in the US and Europe, in a career spanning more than 18 years. Prior to joining Simbec-Orion, Dr. Thibault was Chief Medical Officer at Argenx, and therapeutic area head of Oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. While at Regeneron, Dr. Thibault led the clinical development of VEGF Trap (aflibercept) as well as the fully human antibody products REGN 421 and REGN 910.

Dr. Thibault has extensive clinical development expertise across all stages of biopharmaceutical clinical development, having previously held senior research positions at Johnson & Johnson and Hoffman–La Roche before joining Regeneron.

 

Message Presenter

Ahmad Awada, Head, Medical Oncology Clinic, Jules Bordet Cancer Institute

Ahmad Awada is Head of the Medical Oncology Clinic at Jules Bordet Cancer Institute Brussels, Belgium. Ahmad became Assistant Head of the Medical Oncology Clinic, and then Head of the New Drugs Development Unit at Jules Bordet Institute in April 2005. In addition, from March 1st, 2011, Dr. Awada held the position of Associate Head of Medicine Department. He has a focus in the treatment of solid tumors and, in particular, breast cancer. Dr. Awada took an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy), some of which are already widely used.

Dr. Awada is member of several international scientific societies (ASCO, EORTC, ESMO) and Professor of Clinical Medicine at the Université Libre de Bruxelles.

He has published 26 book chapters and 249 articles in international publications.

Message Presenter

Who Should Attend?

Small/Mid-size drug developers in Europe and USA focused on oncology and rare disease development.

Key job titles include:

  • CEO
  • CSO
  • VP/Director Clinical Operations
  • VP/Director R&D

What You Will Learn

Join this webinar for:

  1. An introduction into how Phase I studies have evolved to meet development objectives 
  2. A discussion of where Phase I design is heading, with a look at whether 3+3 is still the gold standard and what could replace it
  3. The importance of pre-feasibility consultation with specialist oncology sites 
  4. A live Q&A with expert speakers

Xtalks Partner

Simbec Orion Clinical

Orion Clinical is the full-service clinical development division of Simbec-Orion Group.

Founded 20 years ago as a full service CRO, we have expanded through consistent delivery of studies in complex areas. Our operations are based in the United Kingdom, France, USA, Germany and Italy. We have operational staff across mainland Europe (Western, Eastern & Central) and throughout North America.

With over 20 years of experience in the delivery and conduct of oncology clinical trials, including rare & orphan and paediatric studies, we use our skills elegantly to design, execute and deliver our clients’ clinical development needs.

Related Webinars

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account